Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
- First Posted Date
- 2012-09-17
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT01685983
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01685268
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸Clinical Research Alliance, Inc., Lake Success, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 96
- Registration Number
- NCT01685125
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Costantine Albany
- Target Recruit Count
- 72
- Registration Number
- NCT01681433
- Locations
- 🇺🇸
IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States
🇺🇸IU Health Goshen Hospital, Goshen, Indiana, United States
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
- Conditions
- Interventions
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT01664728
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT01655147
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01650194
- Locations
- 🇺🇸
Site US2492 MD Anderson Cancer Ctr, Houston, Texas, United States
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Terence Friedlander, MD
- Target Recruit Count
- 41
- Registration Number
- NCT01637402
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT01576172
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
XL-184+Abiraterone in Post-Chemo CRPC
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01574937
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.